FNIH has selected CRI to be its source of landscape intelligence in immuno-oncology.
Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
A comprehensive, neutral analysis of the global cancer cell therapy landscape; 753 cancer cell therapies in the global development pipeline, with 375 in clinical studies
30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials
Cancer Research Institute iAtlas Poised to Improve Patient Outcomes by Providing Researchers Greater Access to Genomics Data
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for cancer patients.
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to benefit.